FDA DEVICE FACTS
PuraStat-RM
3-D Matrix, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
PuraStat-RM is indicated for the symptomatic management of rectal mucositis, such as radiation proctitis that may be caused by chemotherapy or radiotherapy. The intended use of the subject device is identical to the predicate device’s intended use. The indications for use for the subjec t PuraStat -RM are the same as the predicate ProctiGard (K140558), with the difference being that the subject device includes radiation proctitis that may be caused by chemotherapy or radiotherapy as an example of rectal mucositis. Thus, PuraStat - RM does not have a new intended use. The subject and predicate ProctiGard are both gels that are intended to provide a protective layer over rectal mucosa. The subject PuraStat -RM has the same intended use as the predicate PuraStat -OM (K210211). Both devices are mucoadhesive gels that provide a protective layer over mucosa. The mode of action of PuraStat-RM is achieved in an identical manner to that of PuraStat-OM, i.e., through the formation of a protective layer over the mucosa (over the rectal mucosa rather t han the oral mucosa). Thus, PuraStat-RM does not have a new intended use.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。